对接受中国血友病个体化升级低剂量预防方案(CHIPS)4 年预防治疗的重症 A 型血友病男孩的长期疗效分析。

IF 3.7 3区 医学 Q1 HEMATOLOGY
Wanru Yao , Di Ai , Qing Zhang , Xiaojing Li , Min Zhou , Ningning Zhang , Sheng Yang , Zhenping Chen , Yingzi Zhen , Koon-Hung Luke , Runhui Wu
{"title":"对接受中国血友病个体化升级低剂量预防方案(CHIPS)4 年预防治疗的重症 A 型血友病男孩的长期疗效分析。","authors":"Wanru Yao ,&nbsp;Di Ai ,&nbsp;Qing Zhang ,&nbsp;Xiaojing Li ,&nbsp;Min Zhou ,&nbsp;Ningning Zhang ,&nbsp;Sheng Yang ,&nbsp;Zhenping Chen ,&nbsp;Yingzi Zhen ,&nbsp;Koon-Hung Luke ,&nbsp;Runhui Wu","doi":"10.1016/j.thromres.2024.109110","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up.</p></div><div><h3>Methods</h3><p>Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system.</p></div><div><h3>Results</h3><p>A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5.4 (range 4.3–6.9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18.9 ± 2.8 to 1.7 ± 0.4 (<em>p</em> &lt; 0.001), annual joint bleeding rates from 3.1 ± 0.7 to1.2 ± 0.3 (<em>p</em> &lt; 0.028). 5 out of 8 target joint resolved. Sixteen doses were escalated. At study exit, the heterogeneous treatment outcomes of the SHA boys were 5 at step 4 (20–25 lU/kg, every other day), 10 at step 3 (15–20 IU/kg, 3×/week), 2 at step 2 (10–15 lU/kg, 3×/week) and 1 at step 1 (10–15 lU/kg, 2×/week). The mean FVIII consumption was 2964 IU/kg/year, with savings. The quality of life improved, with Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT, Chinese Version 2.0) scores ranging from 68.8 to 78.8. There was no change in the ultrasound score.</p></div><div><h3>Conclusion</h3><p>Our follow-up data on the 18 SHA boys after completing one year on the CHIPS verify the long-term efficacy of the CHIPS for haemarthrosis reduction, joint health preservation, improvement in the quality of life of the boys and cost savings.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"241 ","pages":"Article 109110"},"PeriodicalIF":3.7000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)\",\"authors\":\"Wanru Yao ,&nbsp;Di Ai ,&nbsp;Qing Zhang ,&nbsp;Xiaojing Li ,&nbsp;Min Zhou ,&nbsp;Ningning Zhang ,&nbsp;Sheng Yang ,&nbsp;Zhenping Chen ,&nbsp;Yingzi Zhen ,&nbsp;Koon-Hung Luke ,&nbsp;Runhui Wu\",\"doi\":\"10.1016/j.thromres.2024.109110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up.</p></div><div><h3>Methods</h3><p>Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system.</p></div><div><h3>Results</h3><p>A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5.4 (range 4.3–6.9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18.9 ± 2.8 to 1.7 ± 0.4 (<em>p</em> &lt; 0.001), annual joint bleeding rates from 3.1 ± 0.7 to1.2 ± 0.3 (<em>p</em> &lt; 0.028). 5 out of 8 target joint resolved. Sixteen doses were escalated. At study exit, the heterogeneous treatment outcomes of the SHA boys were 5 at step 4 (20–25 lU/kg, every other day), 10 at step 3 (15–20 IU/kg, 3×/week), 2 at step 2 (10–15 lU/kg, 3×/week) and 1 at step 1 (10–15 lU/kg, 2×/week). The mean FVIII consumption was 2964 IU/kg/year, with savings. The quality of life improved, with Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT, Chinese Version 2.0) scores ranging from 68.8 to 78.8. There was no change in the ultrasound score.</p></div><div><h3>Conclusion</h3><p>Our follow-up data on the 18 SHA boys after completing one year on the CHIPS verify the long-term efficacy of the CHIPS for haemarthrosis reduction, joint health preservation, improvement in the quality of life of the boys and cost savings.</p></div>\",\"PeriodicalId\":23064,\"journal\":{\"name\":\"Thrombosis research\",\"volume\":\"241 \",\"pages\":\"Article 109110\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombosis research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049384824002421\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049384824002421","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:2016年启动的中国血友病个体化预防研究(CHIPS)报告称,在为期一年的研究中,血友病患者的血友病发生率显著降低。然而,其长期疗效尚需验证。本文总结了18名重症甲型血友病(SHA)患者的临床结果,这些患者在CHIPS中完成了一年的治疗,并接受了3年的随访:临床随访以CHIPS方案为基础(从2018年7月至2021年7月)。根据指数关节出血情况进行升级,每 6 个月通过评分系统对指数关节(两侧脚踝、膝盖和肘部)进行连续超声波(灰度和彩色多普勒)检查:共有 18 名 SHA 患者完成了为期 3 年的研究。有 15 名患者因 COVID-19 在中国流行期间的金融危机而退出。中位年龄为 5.4 岁(4.3-6.9 岁)。血肿明显减少,年平均出血率从 18.9 ± 2.8 降至 1.7 ± 0.4(P 结语):我们对 18 名 SHA 男孩在完成一年的 CHIPS 治疗后的随访数据证实,CHIPS 在减少血性关节病、保护关节健康、改善男孩生活质量和节约成本方面具有长期疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)

Background

The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up.

Methods

Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system.

Results

A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5.4 (range 4.3–6.9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18.9 ± 2.8 to 1.7 ± 0.4 (p < 0.001), annual joint bleeding rates from 3.1 ± 0.7 to1.2 ± 0.3 (p < 0.028). 5 out of 8 target joint resolved. Sixteen doses were escalated. At study exit, the heterogeneous treatment outcomes of the SHA boys were 5 at step 4 (20–25 lU/kg, every other day), 10 at step 3 (15–20 IU/kg, 3×/week), 2 at step 2 (10–15 lU/kg, 3×/week) and 1 at step 1 (10–15 lU/kg, 2×/week). The mean FVIII consumption was 2964 IU/kg/year, with savings. The quality of life improved, with Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT, Chinese Version 2.0) scores ranging from 68.8 to 78.8. There was no change in the ultrasound score.

Conclusion

Our follow-up data on the 18 SHA boys after completing one year on the CHIPS verify the long-term efficacy of the CHIPS for haemarthrosis reduction, joint health preservation, improvement in the quality of life of the boys and cost savings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Thrombosis research
Thrombosis research 医学-外周血管病
CiteScore
14.60
自引率
4.00%
发文量
364
审稿时长
31 days
期刊介绍: Thrombosis Research is an international journal dedicated to the swift dissemination of new information on thrombosis, hemostasis, and vascular biology, aimed at advancing both science and clinical care. The journal publishes peer-reviewed original research, reviews, editorials, opinions, and critiques, covering both basic and clinical studies. Priority is given to research that promises novel approaches in the diagnosis, therapy, prognosis, and prevention of thrombotic and hemorrhagic diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信